Celltrion's Herzuma (Herceptin biosimilar) Receives Marketing Approval in Australia
Shots:
- Herzuma is first biosimilar approved in Australia for the treatment of early breast cancer- locally advanced or metastatic or advance gastric cancer
- Including Herzuma Celltrion has three biosimilar for Australia- Remsima for autoimmune disease- Truxima for blood cancer approved in Aug 2015 and April 2018 respectively
- Celltrion plans to launch Herzuma in Australia after discussing the situation of local market with its subsidiary Celltrion Healthcare
/ article | Ref: Celltrion | Image: Celltrion
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
